Treat-to-target by Email During Urate-lowering Therapy in Gout

Condition(s) studied

Investigational drug(s) / intervention(s)

Cleanweb electronic messaging ePro: Patient and their medecin will communicate regulary via Cleanweb electronic messaging ePro to adapt the posology of THU untill the target urecemia is reached

Usual follow-up: Adaptation and follow-up of ULT according to referring physician's habits

Study summary

Gout is secondary to urate crystal deposition after chronic elevation of serum urate level (SUL). Long-term lowering SUL below 360 µmol/L allows dissolution of deposited crystals and disease cure. There is currently a paradoxical observation: while urate-lowering therapy (ULT) is available and efficient there is an increase of gout prevalence and severity. The apparent failure of ULT in gout management is due to several causes including unadjusted dosage, no SUL verification, irregular follow-up and low treatment compliance.

In contrast, a nurse-led treat-to-target (T2T) strategy with regular adaptations of ULT until reaching SUL target allows gout cure in more than 90% of patients. We hypothesize that an electronic messaging-led T2T strategy will allow obtaining similar results.

The aim of this study is to demonstrate that email-led T2T strategy during ULT is superior to usual care.

Eligibility

Primary outcome measure(s)

• Proportion of patients with target SUL (<360 μmol /L or <300 μmol /L in tophaceous gout) — Month 12

Trial sites (2)

More Assistance Publique - Hôpitaux de Paris trials in France

Other trials for the same condition